Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinlida for post-COVID blood glucose variability in type 2 diabetes
ChiCTR2600116879Phase 4Completed
- Sponsor
- Ruijin Hospital
- Start
- Jan 2026
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of jinlida in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Blood glucose variation. Started Jan 2026; status: completed.
02
Drugs
jinlida
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600116879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116879.